Synovial Sarcoma – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Synovial Sarcoma – Pipeline Review, H1 2018’, provides an overview of the Synovial Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma

– The report reviews pipeline therapeutics for Synovial Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Synovial Sarcoma therapeutics and enlists all their major and minor projects

– The report assesses Synovial Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Synovial Sarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories LLC

CoBioRes NV

Epizyme Inc

GlaxoSmithKline Plc

Immune Design Corp

Immunocore Ltd

Johnson & Johnson

Karyopharm Therapeutics Inc

Merck & Co Inc

Millennium Pharmaceuticals Inc

Novartis AG

OncoTherapy Science Inc

Pfizer Inc

Takara Bio Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Synovial Sarcoma Overview 6

Synovial Sarcoma Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Synovial Sarcoma Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Synovial Sarcoma Companies Involved in Therapeutics Development 21

Advenchen Laboratories LLC 21

CoBioRes NV 21

Epizyme Inc 21

GlaxoSmithKline Plc 22

Immune Design Corp 22

Immunocore Ltd 23

Johnson & Johnson 23

Karyopharm Therapeutics Inc 24

Merck & Co Inc 24

Millennium Pharmaceuticals Inc 25

Novartis AG 25

OncoTherapy Science Inc 25

Pfizer Inc 26

Takara Bio Inc 26

Synovial Sarcoma Drug Profiles 28

ACXT-3102 Drug Profile 28

AL-3818 Drug Profile 29

axitinib Drug Profile 32

Carboxyamidotriazole Orotate Drug Profile 38

Cellular Immunotherapy 1 for Oncology Drug Profile 40

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology Drug Profile 41

CMB-305 Drug Profile 42

CUE-102 Drug Profile 48

everolimus Drug Profile 49

Fusion Protein to Agonize CD3 for Oncology Drug Profile 62

GSK-3377794 Drug Profile 63

OTSA-101 Drug Profile 74

pembrolizumab Drug Profile 75

quisinostat hydrochloride Drug Profile 148

sapanisertib Drug Profile 151

selinexor Drug Profile 155

Small Molecule to Inhibit DNA and Topoisomerase II for Oncology Drug Profile 179

SSTC-104 Drug Profile 180

tazemetostat Drug Profile 181

TBI-1301 Drug Profile 193

Synovial Sarcoma Dormant Projects 195

Synovial Sarcoma Discontinued Products 196

Synovial Sarcoma Product Development Milestones 197

Featured News & Press Releases 197

Appendix 212

Methodology 212

Coverage 212

Secondary Research 212

Primary Research 212

Expert Panel Validation 212

Contact Us 212

Disclaimer 213

List of Tables

List of Tables

Number of Products under Development for Synovial Sarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Synovial Sarcoma Pipeline by Advenchen Laboratories LLC, H1 2018

Synovial Sarcoma Pipeline by CoBioRes NV, H1 2018

Synovial Sarcoma Pipeline by Epizyme Inc, H1 2018

Synovial Sarcoma Pipeline by GlaxoSmithKline Plc, H1 2018

Synovial Sarcoma Pipeline by Immune Design Corp, H1 2018

Synovial Sarcoma Pipeline by Immunocore Ltd, H1 2018

Synovial Sarcoma Pipeline by Johnson & Johnson, H1 2018

Synovial Sarcoma Pipeline by Karyopharm Therapeutics Inc, H1 2018

Synovial Sarcoma Pipeline by Merck & Co Inc, H1 2018

Synovial Sarcoma Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Synovial Sarcoma Pipeline by Novartis AG, H1 2018

Synovial Sarcoma Pipeline by OncoTherapy Science Inc, H1 2018

Synovial Sarcoma Pipeline by Pfizer Inc, H1 2018

Synovial Sarcoma Pipeline by Takara Bio Inc, H1 2018

Synovial Sarcoma Dormant Projects, H1 2018

Synovial Sarcoma Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Synovial Sarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports